Literature DB >> 6210721

Viloxazine plasma concentrations and clinical response.

T R Norman, G D Burrows, B M Davies, K P Maguire, J M Wurm.   

Abstract

Eleven patients suffering from primary depressive illness were treated with 300 mg/d of viloxazine for 29 days. Blood samples were collected at weekly intervals and severity of depression assessed using the Hamilton depression rating scale. Mean plasma viloxazine level for all patients during the trial was 1.20 micrograms/ml and ranged from 0.40 to 2.70 micrograms/ml. No simple relationship between plasma concentration and amelioration score was observed at day (rs = -0.02), day 22 (rs = -0.29) or day 29 (rs = 0.09). No significant difference in plasma concentrations between responders and non-responders was observed at day 29. Side effects were not correlated with plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6210721     DOI: 10.1016/0165-0327(80)90002-6

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  3 in total

Review 1.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

2.  Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon.

Authors:  B S Meldrum; G M Anlezark; H K Adam; D T Greenwood
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

3.  The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.

Authors:  Pierre Baumann; Sven Ulrich; Gabriel Eckermann; Manfred Gerlach; Hans-Joachim Kuss; Gerd Laux; Bruno Müller-Oerlinghausen; Marie Luise Rao; Peter Riederer; Gerald Zernig; Christoph Hiemke
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.